Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 67
News
News | 26 October 2022

CEPI and SK bioscience partner to advance mRNA vaccine technology

CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus

News
News | 26 October 2022

Novartis maintains growth momentum; Confirms FY’22 Group guidance

Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.

News
News | 26 October 2022

Biocon Biologics insulins facility in Malaysia receives EU GMP Certification

The company has received the Certificate of GMP Compliance from the representative European inspection authority, Health Products Regulatory Authority (HPRA), Ireland.

News
News | 24 October 2022

Lupin launches Paliperidone Extended-Release Tablets in US

Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 112 million in the U.S. (IQVIA MAT August 2022).

News
News | 23 October 2022

Jubilant Pharmova Q2FY23 consolidated PAT drops to Rs. 5.49 Cr

The company has reported total income of Rs. 1612.60 crores during the period ended September 30, 2022.

News
News | 23 October 2022

Glenmark Life Sciences Q2FY23 PAT slips to Rs. 106.87 Cr

The company has reported total income of Rs. 519.31 crores during the period ended September 30, 2022.

News
News | 21 October 2022

Aragen to operationalize Hyderabad formulation manufacturing facility by Jan 2023

The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting

News
News | 21 October 2022

Glenmark launches Zita D for adults with Type 2 diabetes having comorbidities

A well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities

News
News | 21 October 2022

Lupin launches Paliperidone Extended-Release Tablets in US

Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of US $112 million in the US

News
News | 21 October 2022

Aarti Drugs Q2 FY23 revenue up 19%; Profit down 5.6%

Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business

News
News | 21 October 2022

Cadila Pharma's Esiloc wins "Best Launch of the Year"

Esiloc was launched at the biggest doctor engagement webinar involving more than 12,000 doctors across the country

News
News | 20 October 2022

Lupin to acquire two inhalation brands from Sunovion for US$75 million

The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.

News
News | 20 October 2022

Parexel bags Global Customer Value Leadership Award

The award recognizes Parexel for delivering the best decentralized trial experience for customers through its capabilities, expertise, and patient recruitment and retention strategies

News
News | 20 October 2022

MedScapeIndia launches a poster of 'Girl Child Anthem'

The girl child anthem will portray a celebration of a girl child.

News
News | 20 October 2022

Syngene Q2 FY23 PAT up 11% to Rs. 102 Cr

Revenue from operations up 26% to Rs. 768 crores

News
News | 19 October 2022

Mandaviya directs officials to focus on strengthening genome sequencing for early detection of variants

He also highlighted the need for community awareness for continued implementation of the Covid Appropriate Behaviour (CAB) especially in view of the upcoming festival season

News
News | 19 October 2022

Inceptua Early Access and Sentynl Therapeutics launch early access program for Nulibry for pediatric patients

MoCD Type A is a rapidly progressive autosomal recessive inborn error of metabolism resulting in toxic sulfite levels causing neurologic sequelae

News
News | 19 October 2022

Merck and the Bill & Melinda Gates Medical Research Institute announce licensing agreement for tuberculosis antibiotic candidates

The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.

Startup

Digitization